Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects

• Drug: Lersivirine
  
  Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
• Drug: Lersivirine
  
  Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
• Drug: Lersivirine
  
  Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
• Drug: Lersivirine
  
  Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
• Drug: Lersivirine
  
  Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days

• Experimental: Lersivirine 500 mg QD fasted (wet granulated tablet)
  
  Intervention: Drug: Lersivirine
• Experimental: Lersivirine 500 mg QD fed (wet granulated tablet)
  
  Intervention: Drug: Lersivirine
• Experimental: Lersivirine 750 mg QD fasted (wet granulated tablet)
  
  Intervention: Drug: Lersivirine
• Experimental: Lersivirine 750 mg QD fed (wet granulated tablet)
  
  Intervention: Drug: Lersivirine
• Active Comparator: Lersivirine 500 mg QD fasted (dry granulated tablet)
  
  Intervention: Drug: Lersivirine

Inclusion Criteria:

• Healthy male and/or female subjects.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
• Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).